Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?
| Image |  |
|---|---|
| Description | scientific article published in 2022 |
| Author/s |
author: Min Shi Robert Peter Gale Neil E Kay |
| Publication date | September 13, 2022 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |